Onyx HealthcareROCO:6569 75 EBITDA Margin % is 18.93% as of Dec. 2025, which is 10% above its 10-year median of 17.17. GuruFocus rates ROCO:6569 with a GF Score™ of 75/100 and a GF Value™ of NT$121.39 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Onyx Healthcare ranks better than 53.92% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Onyx Healthcare's EBITDA for the
three
months ended in Dec. 2025 was NT$60 Mil. Onyx Healthcare's Revenue for the
three
months ended in Dec. 2025 was NT$316 Mil. Therefore, Onyx Healthcare's EBITDA margin for the quarter that ended in Dec. 2025 was 18.93%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Onyx Healthcare EBITDA Margin % Related Terms
Onyx Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Onyx Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6569 vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Onyx Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Healthcare EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Onyx Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Onyx Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onyx Healthcare (ROCO:6569) has a EBITDA Margin % of 18.93% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Onyx Healthcare and its competitors. This is 10% above median its historical median of 17.17. Over the past decade, Onyx Healthcare's EBITDA Margin % has ranged from 11.30 to 22.29. According to the industry distribution chart, Onyx Healthcare ranks #306 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 46.1%.
Is Onyx Healthcare's EBITDA Margin % too high?
Onyx Healthcare's current EBITDA Margin % of 18.93% is 10% above median its 10-year median of 17.17. Over the past 10 years, this metric has ranged from a low of 11.30 to a high of 22.29. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Onyx Healthcare's value of 18.93% is 85% above this industry median. Based on the distribution chart, Onyx Healthcare ranks #306 out of 664 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Onyx Healthcare has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Onyx Healthcare's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Onyx Healthcare ranks #306 out of 664 companies for EBITDA Margin %. This puts Onyx Healthcare in the upper half of its industry. The industry median EBITDA Margin % is 10.24. Onyx Healthcare's value of 18.93% is 85% above this benchmark. Historically, Onyx Healthcare's own EBITDA Margin % has ranged from 11.30 to 22.29 over the past decade. While the company's 10-year median is 17.17 vs. the industry median of 10.24, Onyx Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Healthcare's current EBITDA Margin % of 18.93% is 85% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Onyx Healthcare and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Healthcare's current EBITDA Margin % is 18.93%, which is 10% above median its own 10-year median of 17.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Onyx Healthcare (ROCO:6569) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$121.39, compared to a current price of NT$106.50 — trading 12.3% below its estimated fair value. The current EBITDA Margin % is 18.93%, which is 10% above median its 10-year median of 17.17 and 85% above the Healthcare Providers & Services industry median of 10.24. Onyx Healthcare's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Onyx Healthcare (ROCO:6569), the current EBITDA Margin % is 18.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Onyx Healthcare (ROCO:6569) Overvalued in 2026?
Based on GuruFocus' analysis, Onyx Healthcare stock appears to be undervalued.
The current stock price of NT$106.50 is trading 12.3% below its estimated GF Value™ of NT$121.39.
GuruFocus considers Onyx Healthcare to be Modestly Undervalued.
Key valuation signals for ROCO:6569:
EBITDA Margin %: 18.93% (10% above median its 10-year median of 17.17)
GF Value™: NT$121.39 vs. price of NT$106.50 (12.3% below fair value)
Industry Position: 85% above the Healthcare Providers & Services median (#306 of 664)
No single metric tells the full story. See the ROCO:6569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Onyx Healthcare Inc is engaged in designing, manufacturing, and trading of medical computers and peripherals. The company provides medical products such as AI Ready Medical PC and Tablet, Medical PC & Monitor for Digital OR (ACCEL), Telemedicine, Medical Cart Computer(Venus), Medical Power Panel PC (Mini Venus), Power Bank (UPower), Battery Management System (ORION), Mobile Medical Tablet (MD), Professional Medical All in One PC (ZEUS), etc. It operates in Taiwan, the United States, Europe, and Other countries and generates maximum revenue from Taiwan.
75GF Score
Get the complete analysis for ROCO:6569
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6569 has been successfully added to your 
